Two coronavirus vaccines administered using a nasal spray being developed in Thailand are due to start human trials by the end of this year, after promising results in trials involving mice, a government official said, Report informs referring to Reuters.
Developed by the National Center for Genetic Engineering and Biotechnology, the vaccines are based on the adenovirus and influenza, deputy government spokeswoman Ratchada Thanadirek said.
After conducting trials in mice, the first phase of human trials should start by the end of this year, pending approval from the food and drug regulator, she said.
The trials will also test protection against the Delta variant, Ratchada said, with the second phase due in March next year and a target of production for broader use in mid-2022, if results are good, she said.
Thailand’s other homegrown vaccines, Chulalongkorn University’s mRNA vaccine and an inactivated virus being developed by Mahidol University, are due to start second-phase human trials this month.